Effect of epostane, ZK 98299, and ZK 98734 on the interruption of pregnancy in the rat.
The objective of these studies was to determine whether treatment of 10-day pregnant rats with a combination of epostane (a progesterone biosynthesis inhibitor) and either ZK 98299 or ZK 98734 (progesterone receptor antagonists) would result in additive or synergistic effects on the interruption of pregnancy. When these compounds were tested individually, the order of potency in interrupting pregnancy was ZK 98734 greater than ZK 98299 greater than epostane (50% effective doses 1.3, 4.0, and 35 mg/kg, respectively). Epostane and ZK 98299 were then tested in combination. When epostane was given either 4 h prior to or concurrently with ZK 98299, the combined drug treatment resulted in a significant additive increase in interceptive activity compared to when ZK 98299 was administered alone. In vitro binding studies showed that ZK 98299 and ZK 98734 bound to the rat uterine progesterone receptor in vitro with approximately equal affinity. ZK 98734 bound to the rat thymus glucocorticoid receptor and to the rat ventral prostate androgen receptor with a greater affinity than ZK 98299. The affinity of ZK 98299 for the rat uterine estrogen receptor was weak while the binding of ZK 98734 was not detectable. Thus, the in vitro receptor binding profiles observed were consistent with the known progesterone and glucocorticoid antagonist activities of ZK 98299 and ZK 98734. Overall these findings show that the interceptive activity of epostane and ZK 98299, agents that exert their interceptive activity via different molecular mechanisms, is additive in the 10-day pregnant rat.
Department of Pharmacology, Sterling-Winthrop Research Institute, Rensselaer, New York 12144.
B W
BW
Snyder
J R
JR
Reel
R C
RC
Winneker
F H
FH
Batzold
G O
GO
Potts
D000034:Abortion, Veterinary / Q000139:chemically induced*; D000737:Androstenols / Q000494:pharmacology*; D000818:Animals; D004305:Dose-Response Relationship, Drug; D004963:Estrenes / Q000494:pharmacology*; D005260:Female; D006067:Gonanes / Q000494:pharmacology*; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011374:Progesterone / Q000096:biosynthesis / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D011980:Receptors, Progesterone / Q000037:antagonists & inhibitors / Q000502:physiology; D013997:Time Factors
D000737:Androstenols; D004963:Estrenes; D006067:Gonanes; D011980:Receptors, Progesterone; C048260:lilopristone; D011374:Progesterone; C046855:epostane; C053238:onapristone